Novel insights into metabolic-associated steatotic liver disease preclinical models
© 2024 The Authors. Liver International published by John Wiley & Sons Ltd..
Metabolic-associated steatotic liver disease (MASLD) encompasses a wide spectrum of metabolic conditions associated with an excess of fat accumulation in the liver, ranging from simple hepatic steatosis to cirrhosis and hepatocellular carcinoma. Finding appropriate tools to study its development and progression is essential to address essential unmet therapeutic and staging needs. This review discusses advantages and shortcomings of different dietary, chemical and genetic factors that can be used to mimic this disease and its progression in mice from a hepatic and metabolic point of view. Also, this review will highlight some additional factors and considerations that could have a strong impact on the outcomes of our model to end up providing recommendations and a checklist to facilitate the selection of the appropriate MASLD preclinical model based on clinical aims.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:44 |
|---|---|
| Enthalten in: |
Liver international : official journal of the International Association for the Study of the Liver - 44(2024), 3 vom: 31. März, Seite 644-662 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Montero-Vallejo, Rocío [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Animal models |
|---|
| Anmerkungen: |
Date Completed 01.03.2024 Date Revised 01.03.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1111/liv.15830 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM367821699 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM367821699 | ||
| 003 | DE-627 | ||
| 005 | 20240301232427.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240131s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1111/liv.15830 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1313.xml |
| 035 | |a (DE-627)NLM367821699 | ||
| 035 | |a (NLM)38291855 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Montero-Vallejo, Rocío |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Novel insights into metabolic-associated steatotic liver disease preclinical models |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 01.03.2024 | ||
| 500 | |a Date Revised 01.03.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2024 The Authors. Liver International published by John Wiley & Sons Ltd. | ||
| 520 | |a Metabolic-associated steatotic liver disease (MASLD) encompasses a wide spectrum of metabolic conditions associated with an excess of fat accumulation in the liver, ranging from simple hepatic steatosis to cirrhosis and hepatocellular carcinoma. Finding appropriate tools to study its development and progression is essential to address essential unmet therapeutic and staging needs. This review discusses advantages and shortcomings of different dietary, chemical and genetic factors that can be used to mimic this disease and its progression in mice from a hepatic and metabolic point of view. Also, this review will highlight some additional factors and considerations that could have a strong impact on the outcomes of our model to end up providing recommendations and a checklist to facilitate the selection of the appropriate MASLD preclinical model based on clinical aims | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a MASLD | |
| 650 | 4 | |a animal models | |
| 650 | 4 | |a liver fibrosis | |
| 650 | 4 | |a steatohepatitis | |
| 700 | 1 | |a Maya-Miles, Douglas |e verfasserin |4 aut | |
| 700 | 1 | |a Ampuero, Javier |e verfasserin |4 aut | |
| 700 | 1 | |a Martín, Franz |e verfasserin |4 aut | |
| 700 | 1 | |a Romero-Gómez, Manuel |e verfasserin |4 aut | |
| 700 | 1 | |a Gallego-Durán, Rocío |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Liver international : official journal of the International Association for the Study of the Liver |d 2003 |g 44(2024), 3 vom: 31. März, Seite 644-662 |w (DE-627)NLM124147356 |x 1478-3231 |7 nnns |
| 773 | 1 | 8 | |g volume:44 |g year:2024 |g number:3 |g day:31 |g month:03 |g pages:644-662 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1111/liv.15830 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 44 |j 2024 |e 3 |b 31 |c 03 |h 644-662 | ||